ClinicalTrials.gg
CompletedNCT06895265PCTBACUpdated Mar 26, 2025

Potential Cross-Talk Between Arterial Calcifications

An observational study in Vascular Calcification and Atherosclerosis of Artery, sponsored by Ankara Ataturk Sanatorium Training and Research Hospital. Completed at 1 site in Turkey. Open to participants aged 40 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-03-26.

Sponsored by Ankara Ataturk Sanatorium Training and Research Hospital · Observational

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
921
Ages
40 Years to 90 Years
Sex
All
01

Study summary

Potential Cross-Talk Between Arterial Calcifications Background Vascular calcification is a key component of atherosclerosis. This study investigates the potential correlations between aortic and coronary calcifications detected via abdominal CT, considering age-related variations, to explore the possibility of cross-talk.

Method A total of 921 patients (n=921) [male: 508 (55%), female: 413 (44.7%)] were divided into three age groups: 40-49, 50-69, and 70-90 years. Non-contrast abdominal CT scans were evaluated for calcifications in the coronary arteries, thoracic aorta, abdominal aorta (AA(1): suprarenal, AA(2): renal, AA(3): infrarenal), iliac arteries, and femoral artery. Aortic branches were categorized by calcification levels: none, \<25%, 25-50%, ≥50%

Read the detailed description

Atherosclerosis, a chronic inflammatory condition characterized by the buildup of plaque in the arteries, remains a major global health challenge. Vascular calcification (VC) is a critical component of atherosclerosis . VC can reduce the flexibility and compliance of the blood vessel wall, increase the instability of atherosclerotic plaque, and contribute to intravascular blood clotting, vascular obstruction, heart failure, and acute myocardial infarction. Furthermore, it can exacerbate cardiac workload .

Mediators from peripheral tissues, including inflammation and pro-inflammatory cytokines, are released into the circulation and may affect the heart. Coronary artery disease (CAD) also prompts the heart to release pro-inflammatory cytokines into the bloodstream. Cardiokines, which are heart-derived cytokines, can exert significant endocrine effects on other tissues, leading to damage in various peripheral organs .

Extracellular vesicles (EVs), which attach to receptor cell surfaces, can directly facilitate signal transmission or transfer their contents into the cell to elicit a functional response. EVs have been associated with subclinical atherosclerosis, which is diagnosed through ultrasound imaging of the femoral artery, carotid artery, or abdominal aorta . They have also been shown to play a role in the VC process. EVs facilitate communication between vascular wall cells and bone-vascular, liver-vascular, and adipose-vascular cells to regulate VC .

Understanding the relationship between calcification formations across different arterial regions is crucial for improving our knowledge of atherosclerosis pathophysiology and for facilitating the early diagnosis and follow-up of other affected regions. If such an association exists, it could provide valuable insights into systemic vascular diseases, ischemic patterns, and organ-specific perfusion dynamics.

Methods Patient selection and data collection Non-contrast abdominal CT records of 1,100 patients were reviewed. Records that included observable coronary sections starting from the aorta and femoral artery sections were included in the study. A total of 921 patients [male: 508 (55%), female: 413 (44.7%)] met the inclusion criteria and were divided into three age groups: 40-49, 50-69, and 70-90 years. Patients were classified into subgroups based on their medical records for Hypertension, Hyperlipidemia, Diabetes Mellitus, Coronary Artery Disease, and Chronic Obstructive Pulmonary Disease.

The CT records were retrospectively evaluated for calcifications in the coronary arteries, thoracic and abdominal aorta [AA] [suprarenal [1], renal [2], and infrarenal [3] segments], common iliac arteries [Communis], internal and external iliac arteries [Iliac], and femoral arteries.The CAC score is commonly used to quantify the extent of calcification across all coronary arteries and is typically categorized on a per-patient basis as None, Mild, Moderate, or Severe Following the examination of coronary lesions and the thoracic aorta for calcification, the abdominal aortic area was analyzed. Aortic calcifications were classified in horizontal cross-sectional slices, to some extent, in accordance with the classification proposed by Ehara et alRegional vessel segments were evaluated based on the extent of calcification and categorized as: none, \<25%, 25-50%, and ≥50-100%.

02

Conditions studied

  • Vascular Calcification
  • Atherosclerosis of Artery

Browse trials for

Keywords

  • Vascular calcification
03

In context

Vascular Calcification

82 studies on the registry are indexed under Vascular Calcification; 17 are open to participants now.

This study's enrollment of 921 is above the median of 80 across 23 observational studies indexed under Vascular Calcification.

Browse Vascular Calcification studies →

Lead sponsor

Ankara Ataturk Sanatorium Training and Research Hospital is the lead sponsor of 38 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients aged 40-90 with non-contrast abdominal CT records.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Hypertension, Hyperlipidemia, Diabetes Mellitus, Coronary Artery Disease,

Exclusion criteria

Exclusion Criteria:

Chronic renal failure Hemodialysis patients

-

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
921 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients with abdominal CT records

    The study group consisted of non-contrast abdominal CT records from 921 patients, aged between 40 and 90 years.

06

What researchers measure

Primary outcomes

  1. Recording of coronary and abdominal aorta, as well as common, iliac, and femoral artery calcifications.

    1-coronary artery calcifications, (CAC)\] were visually classified in a simplified manner as either present or absent for a faster assessment 2-Following the examination of coronary lesions and the thoracic aorta for calcification, the abdominal aortic area was analyzed. Aortic calcifications were classified in horizontal cross-sectional slices.Regional vessel segments were evaluated based on the extent of calcification and categorized as: none, \<25%, 25-50%, and ≥50-100%.

    Time frame: "Data were collected over a period of ten months."

07

Study locations

1 site
  • Ankara Atatürk Sanatoryum RTH
    Ankara, Türki̇ye 06570, Turkey
08

References and documents

Individual participant data

Plan to share: Yes — IPD will be shared only upon reasonable request and approval by the study sponsor."

Supporting information: Statistical analysis plan, Clinical study report

Time frame: De-identified individual participant data (IPD) and supporting information will be available starting 6 months after publication of study results. Data will be accessible for a period of 5 years.

Access criteria: Researchers and qualified professionals will be able to access de-identified individual participant data (IPD) and supporting documents, including study protocols and statistical analysis plans. Data will be available through a secure online repository, requiring a formal data-sharing agreement and ethical approval

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06895265
Lead sponsor
Ankara Ataturk Sanatorium Training and Research Hospital
Responsible party
Şahbender Koç (cardıologist, Ankara Ataturk Sanatorium Training and Research Hospital) — Principal investigator
First posted
Mar 26, 2025
Start date
Feb 2, 2024
Primary completion
Dec 30, 2024
Completion
Jan 1, 2025
Last update
Mar 26, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion